Jonathan Aschoff

Jonathan Aschoff Analyst Performance

Analyst at Roth Capital

Jonathan Aschoff is a stock analyst at Roth Capital focused in the healthcare sector, covering 45 publicly traded companies. Over the past year, Jonathan Aschoff has issued 3 stock ratings, including and buy recommendations. While full access to Jonathan Aschoff's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jonathan Aschoff's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
169 Last 12 Years
Buy Recommendations
90.42% 151 Buy Ratings
Companies Covered
45 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy1.8%3 ratings
Buy88.6%148 ratings
Hold5.4%9 ratings
Sell4.2%7 ratings

Out of 167 total stock ratings issued by Jonathan Aschoff at Roth Capital, the majority (88.6%) have been Buy recommendations, followed by 5.4% Hold, 4.2% Sell, and 1.8% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
93.3% of companies on NASDAQ
42 companies
NYSEAMERICAN
2.2% of companies on NYSEAMERICAN
1 company
TSE
2.2% of companies on TSE
1 company
OTCMKTS
2.2% of companies on OTCMKTS
1 company

Jonathan Aschoff, an analyst at Roth Capital, currently covers 45 companies listed on NASDAQ, NYSEAMERICAN, TSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
42 companies
93.3%
Finance
2 companies
4.4%
Industrials
1 company
2.2%

Jonathan Aschoff of Roth Capital specializes in stock coverage within the Healthcare sector, with additional focus on Finance and Industrials companies.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
21 companies
46.7%
PHARMACEUTICALS
19 companies
42.2%
HEALTHCARE EQUIPMENT & SUPPLIES
2 companies
4.4%
FINANCIAL SERVICES
2 companies
4.4%
TRADING COMPANIES & DISTRIBUTORS
1 company
2.2%

About Jonathan Aschoff

Jonathan Aschoff, Ph.D., is a Managing Director, Senior Research Analyst at ROTH, specializing in the biotechnology sector. With over 20 years of experience as a sell-side analyst, he has focused primarily on small and microcap companies within the biotechnology industry. Throughout his career, he has earned several awards in the biotechnology or pharmaceutical sector based on investment return, including recognition from organizations such as The Wall Street Journal, Financial Times, Forbes, Starmine, and Tipranks. Dr. Aschoff earned a B.S. in Biology and a Ph.D. in Microbiology and Molecular Biology from Tufts University. During his Ph.D. studies at Tufts University School of Medicine, his research involved investigating the function of the 3' untranslated avian retroviral genomic mRNA region.
Follow on LinkedIn

Jonathan Aschoff's Ratings History at Roth Capital

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
9/24/2026Initiated Coverage$3.22Buy
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
7/6/2026Boost Price Target$19.57$33.00Buy
Pelthos Therapeutics Inc. stock logo
PTHS
Pelthos Therapeutics
2/26/2026Lower Price Target$23.00$55.00Buy
GT Biopharma, Inc. stock logo
GTBP
GT Biopharma
12/2/2024Upgrade$2.79Strong-Buy